Branded

The Phair Pricing Act of 2018 looks to make more transparent the prices that pharmacy benefit managers and prescription drug plan sponsors negotiate with pharmacies.

Michael Nameth, most recently CEO of Aureus Health, has joined the New York-based company as executive vice president of cloud and specialty pharmacy. He previously was executive vice president of Walgreens Specialty Pharmacy.

Aimovig, a once-monthly self-injected drug, works by blocking the activity of a molecule involved in migraines called calcitonin gene-related peptide, the FDA said.

The U.S. Food and Drug Administration has approved Lucemyra (lofexidine hydrochloride), the first non-opioid treatment for management of opioid withdrawal symptoms in adults.

Gilead said it sought expanded indication for the drug based on a study from the Centers for Disease Control and Prevention that found young adults between 13 and 24 years old comprised 21% of new infections in 2016, with young men who have sex with men making up 81% of new cases.

The U.S. Food and Drug Administration has expanded the approval of Gilenya to treat relapsing multiple sclerosis in children and adolescents age 10 years and older.

Perennial readers of the healthcare industry’s tea leaves, IQVIA — née QuintilesIMS — is once again looking into what the future holds for the healthcare market. The IQVIA Institute for Human Data and Science recently released its report on where the global health market is headed in the next five years.

Drug Store News sat down with Stuart Amos to talk about FlavoRx, its start and where the company sees itself in the marketplace today and in the future.